Literature DB >> 11252167

Molecular cloning, genetic mapping, and expression of the mouse Sf3b1 (SAP155) gene for the U2 snRNP component of spliceosome.

K Isono1, K Abe, Y Tomaru, Y Okazaki, Y Hayashizaki, H Koseki.   

Abstract

SAP155, a subunit of the U2 snRNP, is essential for prespliceosome assembly and splicing catalysis of the major spliceosome. Moreover, the protein has been identified in the minor (U12-dependent) spliceosome. These facts strongly suggest that SAP155 is shared by two distinct complexes owing to its importance in the removal of any type of intron. Here we have isolated a cDNA encoding the 146-kDa mouse homolog, designated Sf3b1. The amino acid sequence of Sf3b1 is very highly conserved among homologs from Schizosaccharomyces pombe (52.4% identity) to human (99.6%), and the C-terminal 825 residues of these Sf3b1 homologs show even higher identities. This C-terminal region shows significant similarity to the PR65 subunit of protein phosphatase 2A, which is composed of 15 tandem repeats of a 39 amino acid sequence. Mouse genome analyses showed Sf3bh1 to be a single-copy gene mapping to the central part of Chromosome (Chr) 1. Northern blot analysis and whole mount in situ hybridization revealed Sf3b1 to be ubiquitously expressed in a variety of adult tissues and mid-gestation embryos.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252167     DOI: 10.1007/s003350010258

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  8 in total

1.  Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1.

Authors:  Kyoichi Isono; Yoko Mizutani-Koseki; Toshihisa Komori; Marion S Schmidt-Zachmann; Haruhiko Koseki
Journal:  Genes Dev       Date:  2005-03-01       Impact factor: 11.361

Review 2.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

3.  A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation.

Authors:  Liya Ma; Bin Liang; Huixian Hu; Wenli Yang; Shengyun Lin; Lihong Cao; Kongfei Li; Yuemin Kuang; Lihong Shou; Weimei Jin; Jianping Lan; Xingnong Ye; Jing Le; Huyi Lei; Jiaping Fu; Ying Lin; Wenhua Jiang; Zhiying Zheng; Songfu Jiang; Lijuan Fu; Chuanyong Su; XiuFeng Yin; Lixia Liu; Jiayue Qin; Jie Jin; Shenxian Qian; Guifang Ouyang; Hongyan Tong
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

4.  The zebrafish sf3b1b460 mutant reveals differential requirements for the sf3b1 pre-mRNA processing gene during neural crest development.

Authors:  Min An; Paul D Henion
Journal:  Int J Dev Biol       Date:  2012       Impact factor: 2.203

5.  A novel locus (CORD12) for autosomal dominant cone-rod dystrophy on chromosome 2q24.2-2q33.1.

Authors:  Gaël Manes; Maxime Hebrard; Béatrice Bocquet; Isabelle Meunier; Delphine Coustes-Chazalette; Audrey Sénéchal; Anne Bolland-Augé; Diana Zelenika; Christian P Hamel
Journal:  BMC Med Genet       Date:  2011-04-15       Impact factor: 2.103

6.  Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma.

Authors:  Hai-Min Hwang; Chang-Kyu Heo; Hye Jung Lee; Sang-Seob Kwak; Won-Hee Lim; Jong-Shin Yoo; Dae-Yuel Yu; Kook Jin Lim; Jeong-Yoon Kim; Eun-Wie Cho
Journal:  J Transl Med       Date:  2018-06-28       Impact factor: 5.531

7.  Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency.

Authors:  George B Kyei; Shanshan Meng; Rashmi Ramani; Austin Niu; Chandraiah Lagisetti; Thomas R Webb; Lee Ratner
Journal:  mBio       Date:  2018-11-06       Impact factor: 7.867

8.  A cancer-specific transcriptional signature in human neoplasia.

Authors:  Francesco Nicassio; Fabrizio Bianchi; Maria Capra; Manuela Vecchi; Stefano Confalonieri; Marco Bianchi; Deborah Pajalunga; Marco Crescenzi; Ian Marc Bonapace; Pier Paolo Di Fiore
Journal:  J Clin Invest       Date:  2005-10-13       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.